Pliant Therapeutics To Present Data From Its Bexotegrast Program At The EASL International Liver Congress June 5-8, 2024

6/6/24 8:06:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $PLRX alert in real time by email

Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced two poster presentations, including a late-breaker, were presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ being held June 5-8, 2024.

Get the next $PLRX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLRX

Date	Price Target	Rating	Analyst
9/9/2024	$46.00 → $33.00	Outperform	Leerink Partners
12/8/2023	$41.00	Overweight	Wells Fargo
5/18/2023	$48.00	Buy	Canaccord Genuity
4/13/2023	$44.00	Outperform	Robert W. Baird
12/14/2022	$33.00	Buy	Stifel
12/7/2022	$42.00	Overweight	JP Morgan
9/1/2022	$36.00	Buy	Citigroup
7/20/2022	$33.00	Outperform	SVB Leerink

More analyst ratings

$PLRX
Leadership Updates

Live Leadership Updates

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
11/7/24 4:05:00 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease
10/1/24 4:35:00 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
9/24/24 8:00:00 AM ET
$ALGS
$HAE
$NVO
$PLRX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced
2/4/24 3:29:07 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f
9/26/23 7:30:00 AM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial. The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant's website. The live audio of the conference call c
9/25/23 4:05:00 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care

Pliant Therapeutics to Participate in Upcoming Investor Events
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events. Evercore 7th Annual HealthCONx Conference Members of Pliant's senior management will meet with investors on Tuesday, December 3, 2024.Citi 2024 Global Healthcare Conference Members of Pliant's senior management will meet with investors on Wednesday, December 4, 2024.Piper Sandler 36th Annual Healthcare Conference Bernard Coulie, M.D., Ph.D. Pliant's President and Chief Exe
11/21/24 8:00:00 AM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.
11/7/24 4:05:00 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease
10/1/24 4:35:00 PM ET
$PLRX
Biotechnology: Pharmaceutical Preparations
Health Care

Pliant Therapeutics To Present Data From Its Bexotegrast Program At The EASL International Liver Congress June 5-8, 2024

Chat with this insight

Recent Analyst Ratings for $PLRX

$PLRX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Pliant Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

Amendment: SEC Form SC 13G/A filed by Pliant Therapeutics Inc.

$PLRX Market Insights

Live Market Insights

Needham Reiterates Buy on Pliant Therapeutics, Maintains $38 Price Target

HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $36 Price Target

Pliant Therapeutics Shares Long-Term Data From The INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast Was Well Tolerated At 320 mg With Continued Antifibrotic And Anti-Cholestatic Activity Displayed Across Multiple Measures

$PLRX SEC Filings

SEC Form 10-Q filed by Pliant Therapeutics Inc.

Pliant Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Pliant Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

$PLRX Leadership Updates

Live Leadership Updates

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

$PLRX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Medical Officer Lefebvre Eric sold $142,408 worth of shares (12,319 units at $11.56), decreasing direct ownership by 5% to 213,052 units (SEC Form 4)

Chief Business Officer Hull Hans sold $114,444 worth of shares (9,900 units at $11.56), decreasing direct ownership by 4% to 227,494 units (SEC Form 4)

Chief Financial Officer Cummings Keith Lamont sold $126,131 worth of shares (10,911 units at $11.56), decreasing direct ownership by 4% to 282,115 units (SEC Form 4)

$PLRX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$PLRX Financials

Live finance-specific insights

$PLRX Press Releases

Fastest customizable press release news feed in the world

Leerink Partners resumed coverage on Pliant Therapeutics with a new price target

Wells Fargo initiated coverage on Pliant Therapeutics with a new price target

Canaccord Genuity initiated coverage on Pliant Therapeutics with a new price target

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from the INTEGRIS-PSC Phase 2a Trial of Bexotegrast 320 mg in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

Pliant Therapeutics to Participate in Upcoming Investor Events

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs

Recent Analyst Ratings for
$PLRX

$PLRX
Large Ownership Changes

$PLRX
Market Insights

$PLRX
SEC Filings

$PLRX
Leadership Updates

$PLRX
Insider Trading

$PLRX
Analyst Ratings

$PLRX
Financials

$PLRX
Press Releases